Shell deepens India market reach through Raj Petro acquisition
Global energy giant Shell
has acquired Mumbai-based
Raj Petro Specialities
to deepen its foothold in the world's third biggest lubricants market in the world, a top company official said.
Shell, which has already invested over $5 billion in India across the energy value chain -- from LNG import terminals and fuel stations to renewable energy and technology centres -- has acquired 100 per cent equity interest in Raj Petro Specialities Pvt Ltd from Germany's Brenntag Group.
"I think the acquisition of Raj Petro marks a very important and a significant milestone for the lubricants business in the country. India is the third biggest lubricants market and from our strategic intent India is one of the important growth markets.
"So we have always been looking at ways by which we can serve more consumers with more products at the right price points," said Mansi Madan Tripathy, Chairman of Shell Group of Companies in India and Vice President - Lubricants Asia Pacific.
Without disclosing financial details of the transaction, she said the acquisition of Raj Petro Specialities by
Shell Lubricants
supports its plans to grow its portfolio and customer base in India, which is one of its key growth markets.
Raj Petro, which has manufacturing facilities at Chennai and Silvassa, offers a wide range of products - from transformer oil to petroleum jellies, white oils, waxes and lubricants. The more than 80-year-old Mumbai-headquartered firm was acquired by Germany's Brenntag in 2017-18.
Shell has a lubricant oil blending plant at Taloja, Maharashtra, and a 200-plus distributors network which will be further strengthened with the addition of Raj Petro.
"Raj Petro adds a new portfolio which is in growing sectors of pharmaceuticals, in personal care, power transmission and white oils which then adds on to our current portfolio to delight our customers in new ways," she said, adding it will help Shell realise new synergies and economies of scale across the lubricants value chain.
India is the world's third largest lubricants market and is one of the four focus countries for Shell Lubricants' business growth strategy.
It serves close to 50,000 outlets through a network of 200 B2C and B2B distributors.
The firm already has long-standing partnerships with OEMs which help it co-create energy solutions. These include some of the world's top automotive manufacturers like Maruti Suzuki, Hyundai Motors, Mahindra Auto, Nissan Motor Corporation, BMW and industrial customers such as Volvo, John Deere, Komatsu and Thermax.
Shell is already expanding its portfolio with innovative solutions, including cooling fluids specifically designed for data centres.
The acquisition of Raj Petro Specialities enables Shell to create more value by growing its lubricants portfolio and customer base in India.
"We also believe that because of the scale, we will also be able to derive synergies through the entire value chain. So from both the customer lens and operational efficiency lens, we do believe that it is going to add significant value for India's lubricants growth plans which is already on a very strong footing but it will take us to a new acceleration," Tripathy said.
She said Raj Petro brings with it a robust operational backbone with two manufacturing plants in Chennai (Tamil Nadu) and Silvassa (Union territory of Dadra and Nagar Haveli and Daman and Diu) with a total production capacity of 350,000 tonnes per annum along with R&D Centres.
Raj Petro not just strengthens local footprint but also brings international presence too. "They are also present in 100 countries globally. So we will have to find the best synergies from a portfolio perspective and then see what will be the footprint from an exact numbers perspective," she added.
This integration unlocks powerful synergies across product development, supply chain efficiency, and customer reach. Raj Petro's diverse portfolio - including white oils, petroleum jelly, and specialty products - enhances Shell's offerings and enables cross-sectoral growth. PTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
20 minutes ago
- Time of India
Graviss chairman moves high court over family settlement feud
Mumbai: Gaurav Ghai , chairman of Graviss Group , which owns and operates the Baskin-Robbins brand in the SAARC region, has approached the Bombay High Court against his father, Ravi Ghai , seeking the court's intervention to appoint an arbitrator for settling a dispute over a family settlement agreement ( FSA ). Justice Somasekhar Sundaresan, in his July 15 order, directed Gaurav Ghai to issue notices to all the parties, and posted the matter for further hearing on August 5. Explore courses from Top Institutes in Select a Course Category Others Data Science Product Management Operations Management Degree MCA CXO others PGDM Management Finance Design Thinking Public Policy Technology Digital Marketing Artificial Intelligence Project Management Leadership Healthcare Data Science Data Analytics healthcare Cybersecurity MBA Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details Skills you'll gain: Duration: 28 Weeks MICA CERT-MICA SBMPR Async India Starts on undefined Get Details Skills you'll gain: Duration: 9 months IIM Lucknow SEPO - IIML CHRO India Starts on undefined Get Details Skills you'll gain: Duration: 16 Weeks Indian School of Business CERT-ISB Transforming HR with Analytics & AI India Starts on undefined Get Details Mumbai-headquartered Graviss Group also has interests in real estate and the hospitality business. However, the dispute is only around the group's listed entity, Graviss Hospitality (GHL), which owns a boutique luxury hotel, InterContinental Marine Drive. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 20 Things Women Should NEVER Wear! Undo "The value of the promoter shares requested by my father in 2021 to be retained in his name, although the beneficial interest in these had passed to me, was a mere ₹25 crore. Over the years, the value of shares has gone up to ₹100 crore. Owing to the rise in value of shares placed under hold/freeze in my favour, he is doing everything to unlock, sell, and monetise his shares in GHL," said Gaurav Ghai when contacted. "The company contributes very minuscule amounts in terms of revenue, but for me, this company has sentimental value since it carries my grandfather's legacy," he added. The genesis of the dispute lies in the family settlement agreement (FSA) of 2021, between Ravi Ghai, his wife Geeta Ghai, and son Gaurav Ghai. According to the agreement, a copy of which was reviewed by ET, Gaurav Ghai would have complete control over the family business, and in lieu of that, his father Ravi Ghai would receive ₹235 crore. Live Events At the time of executing the agreement, Ravi Ghai intended to retain 51% of the shares in GHL during his lifetime. GHL contributes about 10% to the overall revenue of the Graviss Group. In August 2023, the family members entered into a supplemental FSA, under which Ravi Ghai agreed not to sell, encumber, assign, transfer, or create any third-party rights of any nature whatsoever on the 51% of promoter shareholding in GHL. The agreement also stated that Ravi Ghai would bequeath the 51% shareholding controlled by him in GHL to his son Gaurav, post his lifetime. Also, these shares were put under "hold/freeze", according to GHL's stock exchange filing. When contacted, Ravi Ghai denied the existence and validity of any supplemental FSA. "I have never signed, consented to, or authorised anyone to execute such a document on my behalf," said Ravi Ghai, in response to ET's email query.
Time of India
32 minutes ago
- Time of India
Zydus Life's plans for cancer biosimilar hit a legal hurdle
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: The Delhi High Court has issued an interim injunction against Ahmedabad-based drug maker Zydus Lifesciences after a case filed by the US pharma giant Bristol Myers Squibb alleging patent infringement on its blockbuster anticancer drug Opdyta nivolumab ) branded as Opdivo in other restraining order comes as a setback for the Indian drug maker which was running clinical trials in India for the launch of the biosimilar versions of nivolumab. The earliest patent for the drug expires in India on May 2, 2026. The next hearing for the case is August 101-page order issued on July 18 by Justice Mini Pushkarna ruled that the defendants, and all others acting on its behalf, are restrained from manufacturing, using, selling, offering for sale, importing, exporting, advertising, or dealing in any biosimilar/similar biologic of nivolumab, the suit patent, during the pendency of the present suit. The order stated the plaintiffs shall suffer irreparable loss, in case the interim relief as prayed for, was not injections are one of the many latest generation immunotherapy drugs also known as checkpoint inhibitors increasingly used to treat several types of cancers including skin, lungs, kidneys, and Hodgkin lymphoma. It works by activating the body's T-cells or immune cells by targeting a protein called PD-1, thereby unleashing an attack on the cancer vials are sold in India for roughly '2 lakh but for patients who are part of the company's assistance or access programs, the drug is available at a slab-wise discounted the India data is not available, globally Bristol Myers Squibb recorded Opdivo sales of $9.3 billion in 2024. Indian companies have launched biosimilars at half the cost of those charged by their global in Indian patent laws told ET that the court has taken a view that stockpiling of a product during its active patent life amounts to infringement and to release it or flood the market is not legally valid."This opinion may have implications for the other ongoing disputes like the weight-loss drug semaglutide (branded Wegovy) case between Novo Nordisk and Dr. Reddy's Labs or Roche versus Natco for Risdiplam (drug used for a rare disease called spinal muscular atrophy or SMA) case," a senior lawyer petition from BMS noted that Zydus Lifesciences was conducting clinical trials for nivolumab and on its investigation found that the company had plans to launch it during the patent period. The Indian company, it said, had applied for a marketing approval with the central drug regulatory its part, lawyers on behalf of Zydus defended saying its product ZRC-3276 does not infringe upon the existing patents and is following the regulatory was represented by a battery of top lawyers including Harish Salve, Dushyant Dave, and Rajiv Nayar, while Squibb & Sons was represented by Sandeep Sethi, PS Raman, Amit Sibal and Pravin Anand, among others.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Green light for HFT firm Jane Street to re-enter domestic markets
But bourses to closely monitor company's future dealings on ongoing basis Samie Modak Khushboo Tiwari Mumbai Listen to This Article High-frequency trading (HFT) firm Jane Street has been allowed to re-enter the domestic markets after it fulfilled the Securities and Exchange Board of India's (Sebi's) direction to deposit alleged 'unlawful gains' of ₹4,844 crore in an escrow account before July 14. According to sources, Sebi last week informed Jane Street via email that the ban imposed on the New York-based trading firm had been lifted. 'The July 3 interim order clearly states that upon deposit compliance, the restriction on accessing the securities market will cease to apply. However, this has been formally communicated to Jane Street by Sebi through an
